Current status of the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan

Clinical and Experimental Nephrology

Volumn 17, Issue 1, 2013, Pages 51-58

  Sugiyama, Koichi ^a   Sada, Ken Ei ^a   Kurosawa, Michiko ^b   Wada, Jun ^a   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

Anti neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV); Cyclophosphamide; Granulomatosis with polyangiitis (GPA); Microscopic polyangiitis (MPA); Plasma exchange

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; CYTOPLASMIC 3 NEUTROPHIL CYTOPLASMIC ANTIBODY; MYELOPEROXIDASE NEUTROPHIL CYTOPLASMIC ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PERINUCLEAR NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; PROTEINASE 3 NEUTROPHIL CYTOPLASMIC ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; CHEST SYMPTOM; CLINICAL PRACTICE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIALYSIS; DRUG USE; EAR NOSE AND THROAT SYMPTOM; FEMALE; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; GRANULOMATOSIS WITH POLYANGIITIS; HUMAN; JAPAN; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC POLYANGIITIS; MONOTHERAPY; NERVOUS SYSTEM SYMPTOM; PLASMAPHERESIS; RENAL SYMPTOM; SKIN MANIFESTATION; SYMPTOM;

ADRENAL CORTEX HORMONES; AGED; CHI-SQUARE DISTRIBUTION; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE SURVEYS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; KIDNEY; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MICROSCOPIC POLYANGIITIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLASMA EXCHANGE; REGISTRIES; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

EID: 84874115813     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-012-0651-1     Document Type: Article

References (21)

1. Franssen CF, Stegeman CA, Kallenberg CG, Gans RO, De Jong PE, Hoorntje SJ, et al. Antiproteinase 3- and antimyeloperoxidase-associated vasculitis. Kidney Int. 2000;57(6):2195-206.
2. Duna GF, Galperin C, Hoffman GS. Wegener's granulomatosis. Rheum Dis Clin North Am. 1995;21(4):949-86.
3. Watts RA, Scott DG, Jayne DR, Ito-Ihara T, Muso E, Fujimoto S, et al. Renal vasculitis in Japan and the UK - are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant. 2008;23(12):3928-31.
4. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68(3):310-7.
5. Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int. 2007;56(2):87-96.
6. Nakabayashi K, Hashimoto H (editors) Microscopic polyangiitis. Tokyo: Research Group of Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan; 2002.
7. Yoshida M (editor) Wegener's granulomatosis. Tokyo: Research Group of Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan; 2002.
8. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87(11):671-8.
9. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982-92.
10. Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 2000;43(2):414-9.
11. Hashimoto H, Yoshida M, Kobayashi S, Eishi K, Tsusaka N, Nakabayashi K, et al. An epidemiologic nationwide survey of ANCA related vasculitis in Japan.: annual report 1998 of the Research Group for Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan. Tokyo: Research Group of Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan; 1999, pp 213-29.
12. Lane SE, Watts RA, Shepstone L, Scott DG. Primary systemic vasculitis: clinical features and mortality. QJM. 2005;98(2):97-111.
13. Lapraik C, Watts R, Bacon P, Carruthers D, Chakravarty K, D'Cruz D, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford). 2007;46(10):1615-6.
14. Lurati-Ruiz F, Spertini F. Predictive value of antineutrophil cytoplasmic antibodies in small-vessel vasculitis. J Rheumatol. 2005;32(11):2167-72.
15. Oh JS, Lee CK, Kim YG, Nah SS, Moon HB, Yoo B. Clinical features and outcomes of microscopic polyangiitis in Korea. J Korean Med Sci. 2009;24(2):269-74.
16. Ozaki S, Atsumi T, Hayashi T, Ishizu A, Kobayashi S, Kumagai S, et al. Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Mod Rheumatol. 2012;22(3):394-404.
17. Sakai H, Kurokawa K, Koyama A, Arimura Y, Kida H, Shigematsu S. Clinical guildeline for rapidly progressive glomerulonephritis in Japan. Jpn J Nephrol. 2002;44:55-82.
18. Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304(21):2381-8.
19. de Groot K, Harper L, Jayne DR. Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150(10):670-80.
20. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18(7):2180-8.
21. Sakauchi F, Oura A, Ohnishi H, Mori M. Comparison of the clinical features of Japanese patients with primary biliary cirrhosis in 1999 and 2004: utilization of clinical data when patients applied to receive public financial aid. J Epidemiol. 2007;17(6):210-4.